CLEC12A-AS1: A Potential Drug Target and Biomarker (G400002)

Target Name: CLEC12A-AS1

NCBI ID: G400002

CLEC12A-AS1

Other Name(s): CLEC12A antisense RNA 1

CLEC12A-AS1: A Potential Drug Target and Biomarker

CLEC12A-AS1, also known as CLEC12A antisense RNA 1, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and biochemical properties make it an attractive candidate for further research and development as a therapeutic agent.

The discovery of CLEC12A-AS1

CLEC12A-AS1 was first identified as a non-coding RNA molecule using RNA sequencing techniques. The RNA was isolated from human brain tissue and used to treat RNA-mediated RNA interference (RNAi) assays to knockdown the expression of specific genes. The RNA was found to have specificity for the clec12a gene, which is located on chromosome 12q14, and was able to effectively knockdown the expression of the target gene.

Function and mechanism of CLEC12A-AS1

The function of CLEC12A-AS1 is not yet fully understood, but its unique structure and biochemical properties suggest that it plays an important role in the regulation of gene expression. clec12a gene is a known as a gene that encodes a protein involved in the detoxification of xenobiotics, which are harmful substances that can cause harm to the body. The encoded protein is also known as XR1 and is a key enzyme in the detoxification pathway.

The RNA molecule has been shown to interact with the clec12a gene protein and can cause it to become unstable, leading to the clec12a gene being translated into a protein that is involved in the detoxification of xenobiotics. This interaction between the RNA molecule and the gene protein suggests that it plays a role in regulating the expression of the clec12a gene.

CLEC12A-AS1 as a potential drug target

CLEC12A-AS1 has been shown to be a potential drug target by its ability to interact with the clec12a gene protein and cause it to become unstable. This suggests that the molecule could be used as a therapeutic agent to target the clec12a gene and potentially treat diseases where the clec12a gene is involved.

One potential mechanism for the use of CLEC12A-AS1 as a drug target is its ability to cause the clec12a gene to produce more of the encoded protein, which could lead to an increase in the production of harmful substances that can cause disease. By inhibiting the production of this protein, it may be possible to treat diseases where the clec12a gene is involved, such as cancer, neurodegenerative diseases, and respiratory diseases.

Another potential mechanism for the use of CLEC12A-AS1 as a drug target is its ability to cause the clec12a gene to become less expressed, which could lead to a decrease in the production of harmful substances that can cause disease. By increasing the expression of the RNA molecule, it may be possible to treat diseases where the clec12a gene is involved, such as cancer, neurodegenerative diseases, and respiratory diseases.

CLEC12A-AS1 as a biomarker

CLEC12A-AS1 has also been shown to be a potential biomarker for various diseases, including cancer. Its unique structure and biochemical properties make it an attractive candidate for use as a diagnostic or predictive marker for these diseases.

One potential mechanism for the use of CLEC12A-AS1 as a biomarker is its ability to be expressed and stabilized in cancer cells, which could make it an effective indicator of the presence of cancer cells. Additionally, the molecule has been shown to be expressed in various tissues and organs, which could make it a potential

Protein Name: CLEC12A Antisense RNA 1

The "CLEC12A-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLEC12A-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets